探索清除大中分子毒素的临床意义
综述指出透析技术虽进步但患者预后未同步改善,部分归因于难清除的尿毒症毒素;新一代透析膜可有效清除分子量>15 kD的大中分子,已知58种中分子中27种>15 kD,涉及细胞因子等,与慢性炎症、动脉粥样硬化等相关;单中心研究显示清除增加且白蛋白丢失有限,需多中心随机研究评估临床获益。
要点
- 新一代透析膜可清除分子量>15 kD的大中分子,高通透量透析膜清除有限。
- 已知58种中分子中27种>15 kD,包括细胞因子、脂肪因子、激素等。
- 单中心研究显示清除大中分子增加且白蛋白丢失有限,需随机研究验证临床获益。
核心结论
- 清除大中分子(>15 kD)的临床获益尚需严格随机研究评估。
研究设计与样本
- 综述,文献检索已知58种中分子,识别27种分子量>15 kD。
主要发现
- 大中分子包括细胞因子、脂肪因子、激素等,与慢性炎症、动脉粥样硬化、结构性心脏病和继发性免疫缺陷相关。
- 单中心安全性和有效性研究显示,维持性透析患者使用新型膜清除大中分子增加且白蛋白丢失有限。
- 更大规模的多中心研究正在评估这些发现。
关键数值与推荐
- 大中分子定义为分子量>15 kD。
- 已知58种中分子中27种分子量>15 kD。
临床怎么用
- 新型透析膜可能增加大中分子清除且白蛋白丢失有限,但临床获益待随机研究确认。
局限性
- 单中心研究证据有限,需多中心随机研究验证临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dialysis technologies have continued to advance over recent decades; however, these advancements have not always been met with improved patient outcomes. In part, the high morbidity and mortality associated with dialysis have been attributed to a group of uremic toxins, which are described as "difficult to remove." With a new generation of hemodialysis membranes now making meaningful clearance of these molecules possible, it is an apt time to review the clinical relevance of these middle molecules. Our review describes the developments in membrane technology that enable the removal of large middle molecules (molecular mass >15 kD) that is limited with high-flux dialysis membranes. Of the known 58 middle molecules, a literature search identified 27 that have molecular mass >15 kD. This group contains cytokines, adipokines, hormones, and other proteins. These molecules are implicated in chronic inflammation, atherosclerosis, structural heart disease, and secondary immunodeficiency in the literature. Single-center safety and efficacy studies have identified that use of these membranes in maintenance dialysis populations is associated with limited loss of albumin and increased clearance of large middle molecules. Larger, robustly conducted, multicenter studies are now evaluating these findings. After completion of these safety and efficacy studies, the perceived clinical benefits of providing clearance of large middle molecules must be assessed in rigorously conducted, randomized clinical studies.
引用
- Wolley M, Jardine M, Hutchison CA, et al. Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. Clin J Am Soc Nephrol. 2018. PMID: 29507008. doi:10.2215/CJN.10110917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。